Tumour necrosis factor (TNF, or TNF alpha) is a cell-signalling protein involved in inflammation and regulating immune cells. The Trust supported the pioneering research into the role of TNFα and the development of anti-TNFα therapy to manage rheumatoid arthritis, led by Professor Sir Marc Feldmann and Professor Sir Ravinder Maini. This discovery, made with Professor Fionula Brennan 30 years ago, still forms the basis of current treatments for inflammatory diseases.
Other research at the Kennedy Institute supported by the Trust includes research into humoral immune response, molecular imaging and primary cilia in inflammatory signaling.
KENNEDY INSTITUTE, OXFORD
More recently we have focused on supporting the Kennedy Institute of Rheumatology at the University of Oxford and the construction of its purpose-built premises, opened in 2013.
The Kennedy Trust was added to the list of benefactors to Oxford University on the Clarendon Arch pictured above.
INFLAMMATORY DISEASE RESEARCH
Inflammatory disease research is breaking new ground: biologics that target immune pathways, immune profiling that reveals new therapeutic targets, and the impact of new factors such as gut microbes and diet on disease.
INVESTING IN MICROBIOME RESEARCH
The Trust is helping the Kennedy Institute invest in genomics technologies and bioinformatics, and has funded the construction of a germ-free facility to study the impact of gut microbes on health and disease. The Institute is currently one of the few research centres in the UK with specialised facilities for microbiome research.
A-TAP ARTHRITIS THERAPY ACCELERATION PROGRAMME
The Trust is supporting a partnership between the Kennedy institute and the Institute of Translational Medicine of the University of Birmingham to speed up the development of new treatments for arthritis. ATAP develops and tests therapies based on the underlying causes of inflamatory disease, rather that simply treating the clinical symptoms.